Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Novel therapies for children with severe asthma
Top Ten Searches
hla beta 2 probiotics hypo allergenic scid urticaria aeroallergens asthma angioedema hivYour Article Summary
See Latest ArticlesCertolizumab Pegol: In Rheumatoid Arthritis
BioDrugs, 11/10/09
Duggan ST et al. – Certolizumab pegol is a PEGylated humanized Fab? monoclonal antibody that targets and neutralizes both membrane–bound and soluble tumor necrosis factor (TNF)–alpha, preventing inflammation and consequently the destruction of cartilage and bone. Certolizumab pegol has a relatively long elimination half–life of ?2 weeks, allowing subcutaneous administration once every 2 or 4 weeks...In patients with active rheumatoid arthritis who had previously failed to respond to treatment with >=1 disease–modifying anti–rheumatic drug, certolizumab pegol 400 mg every 4 weeks as monotherapy effectively improved ACR responses at all measured timepoints up to 24 weeks, according to data from the randomized, phase III FAST4WARD trial. Certolizumab pegol was generally well tolerated in combination with methotrexate or as monotherapy in phase III trials in patients with rheumatoid arthritis, with most adverse events being of mild to moderate intensity. Infections were the most frequently reported adverse events.
Related Articles
Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis
Arthritis Care and Research, 11/02/09
Relevance Score: 88%
Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: Results from the RAPID 1 randomized controlled trial
Arthritis Research & Therapy, 11/16/09
Relevance Score: 87%
Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: A 3-month, randomized, double-blind, placebo-controlled trial
Clinical Therapeutics, 10/15/09
Relevance Score: 71%
Assistive technology for rheumatoid arthritis
Cochrane Reviews, 10/09/09
Relevance Score: 70%
Abatacept for rheumatoid arthritis
Cochrane Reviews, 10/09/09
Relevance Score: 69%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Autologous blood therapy for common cold—A randomized, double-blind, placebo-controlled trial
Complementary Therapies in Medicine, 12/09/09
Infected atopic dermatitis lesions contain pharmacologic amounts of lipoteichoic acid
Journal of Allergy and Clinical Immunology, 12/08/09
Severe atopic dermatitis treated with everolimus
Journal of Dermatological Treatment , 12/08/09
Today in Rheumatic/Autoimmune...keeping you current
Receive free subspecialty "5-minute updates" via email
Molecular and clinical heterogeneity in CLCN7-dependent osteopetrosis: report of 20 novel mutations
Human Mutation, 12/09/09
Potential role of interleukin-17 in the pathogenesis of bullous pemphigoid
Medical Hypotheses, 12/09/09
The idiotype connection: linking infection and multiple sclerosis
Trends in Immunology, 12/09/09
Sponsor
Article Search
Sponsor